Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE versus ETHMOZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE versus ETHMOZINE.
DRONEDARONE vs ETHMOZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a multichannel blocker that inhibits potassium (IKr, IKs, IKur), sodium (INa), and calcium (ICaL) currents, and exhibits antiadrenergic effects via noncompetitive antagonism of beta-1 and beta-2 receptors. It also prolongs atrial refractoriness and slows atrioventricular conduction.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
400 mg orally twice daily after meals
200-300 mg orally every 8 hours; maximum 900 mg/day.
None Documented
None Documented
Terminal half-life is 13–19 hours; steady state achieved within 4–8 days.
Clinical Note
moderateDronedarone + Levofloxacin
"Dronedarone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateDronedarone + Norfloxacin
"Dronedarone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDronedarone + Gemifloxacin
"Dronedarone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateDronedarone + Ibandronate
"Dronedarone may increase the QTc-prolonging activities of Ibandronate."
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Primarily fecal (≥84%) via biliary excretion; renal excretion accounts for <6% as unchanged drug.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Category C
Category C
Antiarrhythmic
Antiarrhythmic